Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications

Written by Regenerative Medicine

Free to access Regenerative Medicine supplement by the International Stem Cell Banking Initiative (ISCBI) available alongside our March issue

“In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human Embryonic Stem Cell (hESC) lines for research purposes (1), which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines.Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for future development in delivery of differentiated products of human pluripotent stem cell (hPSC) lines.”

by Glyn Stacey et al.

The free to access supplement is available here